Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 10-12 March 2026 – www.ema.europa.eu

13 Mar, 2026

www.ema.europa.eu

CVMP opinions on veterinary medicinal products

The Committee adopted a positive opinion for a marketing authorisation for AviGate S. Infantis, for active immunisation of healthy chickens to reduce faecal excretion and colonisation of internal organs with Salmonella infantis.

The Committee adopted a positive opinion for a marketing authorisation for VeroBlue-3, for active immunisation of sheep to reduce viraemia and pyrexia caused by serotype 3 of the bluetongue virus.

Re-examinations of marketing authorisations in exceptional circumstances

The Committee adopted an opinion on the re-examination of Syvazul BTV-3, a bluetongue virus vaccine (inactivated). The Committee recommended the extension for one year of the validity of the marketing authorisation in exceptional circumstances.

Withdrawal of applications

The Committee was informed of the formal notification from Intervet International B.V. of their decision to withdraw the application for a variation requiring…

Vai all’articolo completo.